289 related articles for article (PubMed ID: 21364029)
1. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.
Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Stefanick ML; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Vitolins M; Kabat GC; Rohan TE; Li CI
Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):454-63. PubMed ID: 21364029
[TBL] [Abstract][Full Text] [Related]
2. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
[TBL] [Abstract][Full Text] [Related]
3. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
[TBL] [Abstract][Full Text] [Related]
4. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
5. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
Fagherazzi G; Chabbert-Buffet N; Fabre A; Guillas G; Boutron-Ruault MC; Mesrine S; Clavel-Chapelon F
Int J Obes (Lond); 2012 Mar; 36(3):431-9. PubMed ID: 21427693
[TBL] [Abstract][Full Text] [Related]
6. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
7. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
[TBL] [Abstract][Full Text] [Related]
8. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
10. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer.
Phipps AI; Buist DS; Malone KE; Barlow WE; Porter PL; Kerlikowske K; O'Meara ES; Li CI
Ann Epidemiol; 2012 May; 22(5):340-8. PubMed ID: 22366170
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
12. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.
Phipps AI; Malone KE; Porter PL; Daling JR; Li CI
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2078-86. PubMed ID: 18664548
[TBL] [Abstract][Full Text] [Related]
13. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
14. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study.
Cui Y; Shikany JM; Liu S; Shagufta Y; Rohan TE
Am J Clin Nutr; 2008 Apr; 87(4):1009-18. PubMed ID: 18400726
[TBL] [Abstract][Full Text] [Related]
15. Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women.
Miyagawa Y; Miyake T; Yanai A; Murase K; Imamura M; Ichii S; Takatsuka Y; Ito T; Hirota S; Saito M; Kotoura Y; Miyauchi K; Fujimoto Y; Hatada T; Sasa M; Miyoshi Y
Breast Cancer; 2015 Jul; 22(4):399-405. PubMed ID: 24000037
[TBL] [Abstract][Full Text] [Related]
16. Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk.
Cui Y; Deming-Halverson SL; Beeghly-Fadiel A; Lipworth L; Shrubsole MJ; Fair AM; Shu XO; Zheng W
Clin Cancer Res; 2014 Mar; 20(5):1169-78. PubMed ID: 24423614
[TBL] [Abstract][Full Text] [Related]
17. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.
Zhang X; Eliassen AH; Tamimi RM; Hazra A; Beck AH; Brown M; Collins LC; Rosner B; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):962-8. PubMed ID: 25855627
[TBL] [Abstract][Full Text] [Related]
18. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Colleoni M; Cole BF; Viale G; Regan MM; Price KN; Maiorano E; Mastropasqua MG; Crivellari D; Gelber RD; Goldhirsch A; Coates AS; Gusterson BA
J Clin Oncol; 2010 Jun; 28(18):2966-73. PubMed ID: 20458051
[TBL] [Abstract][Full Text] [Related]
19. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in anthropometric measures as risk factors for triple-negative breast cancer.
Wang F; Kroenke CH; Pan K; Shadyab AH; Chlebowski RT; Wactawski-Wende J; Qi L; Luo J
Cancer Causes Control; 2022 Dec; 33(12):1413-1419. PubMed ID: 36129619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
